Pharmaceutical company Gedeon Richter UK has received full marketing and distribution rights for neuropsychiatry treatment Reagila (cariprazine). Reagila was acquired by Gedeon Richter UK from Recordati Pharmaceuticals, with Gedeon Richter picking up the rights for UK promotion of cariprazine. The drug is currently licensed in the UK… Read More
Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder. Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Read More
New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model. The company says the findings support the continued clinical development… Read More
Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million. The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression. Through a… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More
Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More
Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in… Read More
A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. NMRA-266, an allosteric modulator that works through a mechanism that has been clinically validated in the… Read More
Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years? MM: Although our… Read More
The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This round-up was compiled by DDW’s Diana Spencer. Amid continued… Read More
The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This round-up was compiled by DDW’s Diana Spencer and reflects… Read More
News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry. Partnerships… Read More
